Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland-Reference-Cited by-同舟云学术

Cost–effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland

Published:2023-08-02 Issue: Volume: Page:
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Critchlow Simone¹^ORCID,Bullement Ash¹^ORCID,Crabb Simon²^ORCID,Jones Robert³^ORCID,Christoforou Katerina⁴,Amin Amerah⁴,Xiao Ying⁵,Kapetanakis Venediktos⁵,Benedict Ágnes⁶,Chang Jane⁷,Kearney Mairead⁸,Eccleston Anthony⁹

Affiliation:

1. Delta Hat, Bramley House, Nottingham, NG10 3SX, UK

2. University of Southampton, University Road, Southampton, SO17 1BJ, UK

3. University of Glasgow, University Avenue, Glasgow, G12 8QQ, UK

4. Merck Serono Ltd. 5 New Square, Feltham, TW14 8HA, UK, an affiliate of Merck KGaA

5. Evidera, 201 Talgarth Road, London, W6 8BJ, UK

6. Evidera, Bocskai út 134-146, Budapest, 1113, Hungary

7. Pfizer, 235 E 42nd Street, New York, NY 10017, USA

8. Merck Healthcare KGaA, Frankfurter Strasse 250, Darmstadt, 64293, Germany

9. Pfizer, Dorking Road, Tadworth, Surrey, KT20 7NS, UK

Abstract

Aim: The cost–effectiveness of avelumab first-line maintenance treatment for locally advanced or metastatic urothelial carcinoma in Scotland was assessed. Materials & methods: A partitioned survival model was developed comparing avelumab plus best supportive care (BSC) versus BSC alone, incorporating JAVELIN Bladder 100 trial data, costs from national databases and published literature and clinical expert validation of assumptions. Incremental cost–effectiveness ratio (ICER) was estimated using lifetime costs and quality-adjusted life-years (QALY). Results: Avelumab plus BSC had incremental costs of £9446 and a QALY gain of 0.63, leading to a base-case (deterministic) ICER of £15,046 per QALY gained, supported by robust sensitivity analyses. Conclusion: Avelumab first-line maintenance is likely to be a cost-effective treatment for locally advanced or metastatic urothelial carcinoma in Scotland.

Funder

Pfizer

The healthcare business of Merck KGaA, Darmstadt, Germany

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2023-0372

Reference44 articles.

1. Cancer.Net. Bladder cancer: introduction. http://www.cancer.net/cancer-types/bladder-cancer/introduction (Accessed: 21 April 2023).

2. Public Health Scotland. Cancer statistics: bladder cancer. http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/Bladder/ (Accessed: 21 April 2023).

3. Davies F, Knott C, Kerr C, Lockhat M, Adedokun L. Utilising routine health data to establish a standing cohort of patients with metastatic bladder cancer: initial results and algorithm defining disease progression. europe2020-ispor.ipostersessions.com/Default.aspx?s=95-56-36-01-D0-00-15-AA-7F-9F-D4-84-35-78-E1-C7 (Accessed: 21 April 2023).

4. PCN341 Treatment Patterns and Clinical Outcomes in Patients with Locally Advanced or Metastatic Urothelial Cancer in England: Results of a Longitudinal Observational Cohort Study

5. Current Treatment and Outcomes Benchmark for Locally Advanced or Metastatic Urothelial Cancer From a Large UK-Based Single Centre